|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seiwert TY, Salama JK and Vokes EE: The
chemoradiation paradigm in head and neck cancer. Nat Clin Pract
Oncol. 4:156–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dassonville O, Formento JL, Francoual M,
Ramaioli A, Santini J, Schneider M, Demard F and Milano G:
Expression of epidermal growth factor receptor and survival in
upper aerodigestive tract cancer. J Clin Oncol. 11:1873–1878. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu W and Zhao S: Metabolic changes in
cancer: Beyond the Warburg effect. Acta Biochim Biophys Sin
(Shanghai). 45:18–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto M, Inohara H and Nakagawa T:
Targeting metabolic pathways for head and neck cancers
therapeutics. Cancer Metastasis Rev. 36:503–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beloueche-Babari M, Box C, Arunan V,
Parkes HG, Valenti M, De Haven Brandon A, Jackson LE, Eccles SA and
Leach MO: Acquired resistance to EGFR tyrosine kinase inhibitors
alters the metabolism of human head and neck squamous carcinoma
cells and xenograft tumours. Br J Cancer. 112:1206–1214. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kircher MF, Hricak H and Larson SM:
Molecular imaging for personalized cancer care. Mol Oncol.
6:182–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baschnagel AM, Wobb JL, Dilworth JT,
Williams L, Eskandari M, Wu D, Pruetz BL and Wilson GD: The
association of (18)F-FDG PET and glucose metabolism biomarkers
GLUT1 and HK2 in p16 positive and negative head and neck squamous
cell carcinomas. Radiother Oncol. 117:118–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carvalho KC, Cunha IW, Rocha RM, Ayala FR,
Cajaíba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG and Soares
FA: GLUT1 expression in malignant tumors and its use as an
immunodiagnostic marker. Clinics (Sao Paulo). 66:965–972. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kunkel M, Reichert TE, Benz P, Lehr HA,
Jeong JH, Wieand S, Bartenstein P, Wagner W and Whiteside TL:
Overexpression of Glut-1 and increased glucose metabolism in tumors
are associated with a poor prognosis in patients with oral squamous
cell carcinoma. Cancer. 97:1015–1024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YD, Li SJ and Liao JX: Inhibition of
glucose transporter 1 (GLUT1) chemosensitized head and neck cancer
cells to cisplatin. Technol Cancer Res Treat. 12:525–535. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jedlinski A, Ansell A, Johansson AC and
Roberg K: EGFR status and EGFR ligand expression influence the
treatment response of head and neck cancer cell lines. J Oral
Pathol Med. 42:26–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jerhammar F, Johansson AC, Ceder R,
Welander J, Jansson A, Grafström RC, Söderkvist P and Roberg K:
YAP1 is a potential biomarker for cetuximab resistance in head and
neck cancer. Oral Oncol. 50:832–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roberg K, Ceder R, Farnebo L,
Norberg-Spaak L and Grafstrom RC: Multiple genotypic aberrances
associate to terminal differentiation-deficiency of an oral
squamous cell carcinoma in serum-free culture. Differentiation.
76:868–880. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leutenegger CM, Mislin CN, Sigrist B,
Ehrengruber MU, Hofmann-Lehmann R and Lutz H: Quantitative
real-time PCR for the measurement of feline cytokine mRNA. Vet
Immunol Immunopathol. 71:291–305. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jedlinski A, Garvin S, Johansson AC,
Edqvist PH, Ponten F and Roberg K: Cetuximab sensitivity of head
and neck squamous cell carcinoma xenografts is associated with
treatment-induced reduction in EGFR, pEGFR, and pSrc. J Oral Pathol
Med. 46:717–724. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hentschel M, Paulus T, Mix M, Moser E,
Nitzsche EU and Brink I: Analysis of blood flow and glucose
metabolism in mammary carcinomas and normal breast: A H2(15)O PET
and 18F-FDG PET study. Nucl Med Commun. 28:789–797. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Machtay M, Natwa M, Andrel J, Hyslop T,
Anne PR, Lavarino J, Intenzo CM and Keane W: Pretreatment FDG-PET
standardized uptake value as a prognostic factor for outcome in
head and neck cancer. Head Neck. 31:195–201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Orabi H, Al-Shareaif A and El Galefi M:
Gamma-ray measurements of naturally occurring radioactive sample
from Alkharje City. J Radioanal Nucl Chem. 269:99–102. 2006.
View Article : Google Scholar
|
|
21
|
Behzadi A, Ung Y, Lowe V and Deschamps C:
The role of positron emission tomography in the management of
non-small cell lung cancer. Can J Surg. 52:235–242. 2009.PubMed/NCBI
|
|
22
|
Gould MK, Maclean CC, Kuschner WG, Rydzak
CE and Owens DK: Accuracy of positron emission tomography for
diagnosis of pulmonary nodules and mass lesions: A meta-analysis.
JAMA. 285:914–924. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao K, Yang SY, Zhou SH, Dong MJ, Bao YY
and Yao HT: Fluorodeoxyglucose uptake in laryngeal carcinoma is
associated with the expression of glucose transporter-1 and
hypoxia-inducible-factor-1α and the phosphoinositide
3-kinase/protein kinase B pathway. Oncol Lett. 7:984–990. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamada T, Uchida M, Kwang-Lee K, Kitamura
N, Yoshimura T, Sasabe E and Yamamoto T: Correlation of
metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral
squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral
Radiol. 113:464–471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mason NS, Lopresti BJ, Ruszkiewicz J, Dong
X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR and
Thomas SM: Utility of 3′-[(18)F]fluoro-3′-deoxythymidine as a PET
tracer to monitor response to gene therapy in a xenograft model of
head and neck carcinoma. Am J Nucl Med Mol Imaging. 3:16–31.
2013.PubMed/NCBI
|
|
26
|
Miyawaki A, Ikeda R, Hijioka H, Ishida T,
Ushiyama M, Nozoe E and Nakamura N: SUVmax of FDG-PET correlates
with the effects of neoadjuvant chemoradiotherapy for oral squamous
cell carcinoma. Oncol Rep. 23:1205–1212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen LF, Zhao X, Zhou SH, Lu ZJ, Zhao K,
Fan J and Zhou ML: In vivo evaluation of the effects of
simultaneous inhibition of GLUT-1 and HIF-1alpha by antisense
oligodeoxynucleotides on the radiosensitivity of laryngeal
carcinoma using micro 18F-FDG PET/CT. Oncotarget. 8:34709–34726.
2017.PubMed/NCBI
|
|
28
|
Starska K, Forma E, Jozwiak P, Bryś M,
Lewy-Trenda I, Brzezińska-Błaszczyk E and Krześlak A: Gene and
protein expression of glucose transporter 1 and glucose transporter
3 in human laryngeal cancer-the relationship with regulatory
hypoxia-inducible factor-1α expression, tumor invasiveness, and
patient prognosis. Tumour Biol. 36:2309–2321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wiechec E, Hansson KT, Alexandersson L,
Jonsson JI and Roberg K: Hypoxia mediates differential response to
anti-EGFR therapy in HNSCC cells. Int J Mol Sci. 18:E9432017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ben-Haim S and Ell P: 18F-FDG PET and
PET/CT in the evaluation of cancer treatment response. J Nucl Med.
50:88–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
